Limits...
Early administration of IL-6RA does not prevent radiation-induced lung injury in mice.

Ogata T, Yamazaki H, Teshima T, Kihara A, Suzumoto Y, Inoue T, Nishimoto N, Matsuura N - Radiat Oncol (2010)

Bottom Line: Interleukin-6 (IL-6) is a pleiotropic cytokine and plays important roles in the regulation of immune response and inflammation.Enzyme-linked immunosorbent assay was used to examine the plasma level of IL-6 and serum amyloid A (SAA).Our findings suggest that early treatment with IL-6RA after irradiation alone does not protect against radiation-induced lung injury.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Radiation Oncology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, Japan. ogata@radonc.med.osaka-u.ac.jp

ABSTRACT

Background: Radiation pneumonia and subsequent radiation lung fibrosis are major dose-limiting complications for patients undergoing thoracic radiotherapy. Interleukin-6 (IL-6) is a pleiotropic cytokine and plays important roles in the regulation of immune response and inflammation. The purpose of this study was to investigate whether anti-IL-6 monoclonal receptor antibody (IL-6RA) could ameliorate radiation-induced lung injury in mice.

Methods: BALB/cAnNCrj mice having received thoracic irradiation of 21 Gy were injected intraperitoneally with IL-6RA (MR16-1) or control rat IgG twice, immediately and seven days after irradiation. Enzyme-linked immunosorbent assay was used to examine the plasma level of IL-6 and serum amyloid A (SAA). Lung injury was assessed by histological staining with haematoxylin and eosin or Azan, measuring lung weight, and hydroxyproline.

Results: The mice treated with IL-6RA did not survive significantly longer than the rat IgG control. We observed marked up-regulation of IL-6 in mice treated with IL-6RA 150 days after irradiation, whereas IL-6RA temporarily suppressed early radiation-induced increase in the IL-6 release level. Histopathologic assessment showed no differences in lung section or lung weight between mice treated with IL-6RA and control.

Conclusions: Our findings suggest that early treatment with IL-6RA after irradiation alone does not protect against radiation-induced lung injury.

Show MeSH

Related in: MedlinePlus

Histological analyses using H&E staining for irradiated murine lung tissue.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC2864283&req=5

Figure 4: Histological analyses using H&E staining for irradiated murine lung tissue.

Mentions: The time course of H&E and Azan staining in the lung tissue after irradiation is shown in Figures 4 and 5, demonstrating that the extent and severity of lung damage was not significantly reduced in the IL-6RA group in comparison with the control group.


Early administration of IL-6RA does not prevent radiation-induced lung injury in mice.

Ogata T, Yamazaki H, Teshima T, Kihara A, Suzumoto Y, Inoue T, Nishimoto N, Matsuura N - Radiat Oncol (2010)

Histological analyses using H&E staining for irradiated murine lung tissue.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC2864283&req=5

Figure 4: Histological analyses using H&E staining for irradiated murine lung tissue.
Mentions: The time course of H&E and Azan staining in the lung tissue after irradiation is shown in Figures 4 and 5, demonstrating that the extent and severity of lung damage was not significantly reduced in the IL-6RA group in comparison with the control group.

Bottom Line: Interleukin-6 (IL-6) is a pleiotropic cytokine and plays important roles in the regulation of immune response and inflammation.Enzyme-linked immunosorbent assay was used to examine the plasma level of IL-6 and serum amyloid A (SAA).Our findings suggest that early treatment with IL-6RA after irradiation alone does not protect against radiation-induced lung injury.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Radiation Oncology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, Japan. ogata@radonc.med.osaka-u.ac.jp

ABSTRACT

Background: Radiation pneumonia and subsequent radiation lung fibrosis are major dose-limiting complications for patients undergoing thoracic radiotherapy. Interleukin-6 (IL-6) is a pleiotropic cytokine and plays important roles in the regulation of immune response and inflammation. The purpose of this study was to investigate whether anti-IL-6 monoclonal receptor antibody (IL-6RA) could ameliorate radiation-induced lung injury in mice.

Methods: BALB/cAnNCrj mice having received thoracic irradiation of 21 Gy were injected intraperitoneally with IL-6RA (MR16-1) or control rat IgG twice, immediately and seven days after irradiation. Enzyme-linked immunosorbent assay was used to examine the plasma level of IL-6 and serum amyloid A (SAA). Lung injury was assessed by histological staining with haematoxylin and eosin or Azan, measuring lung weight, and hydroxyproline.

Results: The mice treated with IL-6RA did not survive significantly longer than the rat IgG control. We observed marked up-regulation of IL-6 in mice treated with IL-6RA 150 days after irradiation, whereas IL-6RA temporarily suppressed early radiation-induced increase in the IL-6 release level. Histopathologic assessment showed no differences in lung section or lung weight between mice treated with IL-6RA and control.

Conclusions: Our findings suggest that early treatment with IL-6RA after irradiation alone does not protect against radiation-induced lung injury.

Show MeSH
Related in: MedlinePlus